Back to Search
Start Over
Non-Insulin Injectables
- Source :
- Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome ISBN: 9781603274401
- Publication Year :
- 2010
- Publisher :
- Humana Press, 2010.
-
Abstract
- The description of the incretin effect was first described in 1964 by Elwick when he observed a greater insulin secretory response if glucose was administered orally compared to intravenously despite similar elevations in plasma glucose. This incretin effect is attributed to the release of peptide hormones from the K and L cells in the intestines in the response to eating, so that approximately 60% of the insulin subsequently secreted is related directly to the effect of incretins [1]. Glucagon like peptide-1 (GLP-1) is secreted by the L cells, suppresses postprandial glucagon secretion, reduces appetite and stimulates insulin secretion in a dose dependent manner.
- Subjects :
- endocrine system
medicine.medical_specialty
Chemistry
Insulin
medicine.medical_treatment
media_common.quotation_subject
digestive, oral, and skin physiology
Glucagon secretion
Incretin
Appetite
Peptide hormone
Glucagon
Endocrinology
Postprandial
Internal medicine
medicine
Insulin secretion
hormones, hormone substitutes, and hormone antagonists
media_common
Subjects
Details
- ISBN :
- 978-1-60327-440-1
- ISBNs :
- 9781603274401
- Database :
- OpenAIRE
- Journal :
- Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome ISBN: 9781603274401
- Accession number :
- edsair.doi...........956641bb3a5e8daa35b28c32b82f6a5b